Natural Alternatives Change in Accounts Payable 2012-2025 | NAII

Natural Alternatives change in accounts payable from 2012 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Natural Alternatives Change in Accounts Payable 2012-2025 | NAII

Natural Alternatives change in accounts payable from 2012 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$70.5B
Zoetis (ZTS)$69.4B
Takeda Pharmaceutical (TAK)$49.4B
Daiichi Sankyo, - (DSNKY)$48.3B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$27.6B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$17B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14.1B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.4B
Orion OYJ (ORINY)$11.3B
Eisai (ESAIY)$9.3B
Madrigal Pharmaceuticals (MDGL)$9.2B
Corcept Therapeutics (CORT)$7.4B
Grifols, S.A (GRFS)$7B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.6B
Hypermarcas (HYPMY)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B